secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vericel Corp (VCEL)
CIK:        0000887359
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001628280-25-036854
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vericel Q2 revenue $63.2M (+20% YoY); net loss narrows to $0.6M; adj. EBITDA up 112% to $13.4M
--------------------------------------------------------------------------------

- Record Q2 total revenue $63.2M, up 20% YoY; MACI revenue $53.5M, up 21%.
- Gross margin improved to 74% (vs 70% Q2 2024); non-GAAP adj. EBITDA $13.4M, 112% growth, margin 21%.
- Net loss narrowed to $0.6M ($0.01/sh) from $4.7M loss ($0.10/sh) last year.
- Cash & investments $164M, no debt; reaffirmed FY guidance: MACI revenue growth low 20s, gross margin 74%, adj. EBITDA margin 26%.
- Received FDA IND clearance for Phase 3 MACI Ankle study; ~600 MACI Arthro surgeons trained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887359/000162828025036854/0001628280-25-036854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887359/000162828025036854/vcel-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-036854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer